Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

BACKGROUND: Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I–II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, to standard chemoradiotherapy. The case presented here is a complete pathological response seen in a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Willett, Christopher G, Duda, Dan G, di Tomaso, Emmanuelle, Boucher, Yves, Czito, Brian G, Vujaskovic, Zeljko, Vlahovic, Gordana, Bendell, Johanna, Cohen, Kenneth S, Hurwitz, Herbert I, Bentley, Rex, Lauwers, Gregory Y, Poleski, Martin, Wong, Terence Z, Paulson, Erik, Ludwig, Kirk A, Jain, Rakesh K
Format: Artigo
Jezik:Inglês
Izdano: 2007
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2686127/
https://ncbi.nlm.nih.gov/pubmed/17464339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncponc0813
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items